BECN1 and B-cell chronic lymphocytic leukemia: Venetoclax is primarily used in the treatment of chronic lymphocytic leukemia (CLL), and its mechanism of action on autophagic activity is linked to its ability to activate Beclin-1 by releasing it from its complex with Bcl-2 [16].